Maternal Use of Anti-Obesity Drugs and Infant Congenital Malformations

  • Bengt Källén


Relatively little data are available on the use of modern anti-obesity drugs in early pregnancy. There seems to be no effect of the use of orlistat but an indicated doubling of malformation risk after sibutramine which should be avoided in early pregnancy.


  1. Blomberg M, Källén B. Maternal obesity and morbid obesity: the risk for birth defects in the offspring. Birth Defects Res A Clin Mol Teratol. 2010;88:35–40.PubMedGoogle Scholar
  2. De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Early first-trimester sibutramine exposure: pregnancy outcome and neonatal follow-up. Drug Saf. 2006;29:255–9.CrossRefGoogle Scholar
  3. Heinonen OP, Sloan D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group, Inc.; 1977.Google Scholar
  4. Källén AJB. Antiobesity drugs in early pregnancy and congenital malformations in the offspring. Obes Res Clin Pract. 2014;8:e571–6.CrossRefGoogle Scholar
  5. Perrio MJ, Wilton LV, Shakir AW. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity. 2007;15:2712–22.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations